Skip to main content
SpringerLink
Log in

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells

  • Original Articles
  • Immunotherapy, Bispecific Monoclonal Antibodies, T Cell Targeting, T Cell Activation, Carcinoma
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

In a pilot clinical study carcinoma patients with malignant ascites or pleural exudates have been treated locally with autologous lymphocytes activated ex vivo and redirected towards tumour cells with bispecific monoclonal antibodies. BIS-1, the bispecific monoclonal antibody used in this study, combines specificity against a tumour-associated antigen, AMOC-31, present on carcinomas, with a specificity against the CD3 complex on T lymphocytes. Patients selected for treatment had malignant pleural or peritoneal effusions. Treatment consisted of isolating autologous peripheral blood lymphocytes, ex vivo activation, incubation with bispecific monoclonal antibodies and injection at the effusion site of these BIS-1-redirected lymphocytes. To evaluate the effects of the bispecific monoclonal antibody, five patients received treatments with activated lymphocytes without bispecific antibodies. Effusion samples taken before and at various times after treatment were analysed by immunocytology and for the presence of the soluble factors carcinoembryonic antigen (CEA), interleukin-6 (IL-6), tumour necrosis factor (TNF), C-reactive protein and soluble CD8. In this way both immune activation and anti-tumour activity could be monitored. Conjugate formation between tumour cells and activated lymphocytes was seen as soon as 4 h after injection of BIS-1-redirected activated lymphocytes, followed by a disappearance or reduction of tumour cells after 24–48 h. In parallel with this, the soluble tumour marker CEA decreased in the effusion fluid following injection with the BIS-1-redirected lymphocytes. Furthermore, a steep increase in local granulocyte numbers was observed in the effusion fluid, which reached a maximum 24–48 h after the start of the treatment. Also levels of IL-6 and TNF were greatly elevated. The data suggest tha the treatment induces both antitumour activity and a strong local inflammatory reaction. This is accompanied by no or only minor local and systemic toxicity, i.e. mild fever, which disappeared as the local inflammatory reaction diminished 48–72 h after treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Appelgate KG, Balch CM, Pellis NR (1990) in vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumorinfiltrating lymphocytes. Cancer Res 50: 7153

    PubMed  Google Scholar 

  2. Bolhuis RLH, Sturm E, Braakman E (1991) T cell targeting in cancer therapy. Cancer Immunol Imunother 34: 1

    Google Scholar 

  3. Blakely DC, Thorpe PE (1988) An overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunocon Radiopharmacol 1: 1

    Google Scholar 

  4. Braakman E, Goedegebuure PS, Vreugdenhil RJ, Segal DM, Shaw S, Bolhuis RLH (1990) ICAM-1-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int J Cancer 46: 475

    PubMed  Google Scholar 

  5. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL lymphoma with bispecific antibodies. J Immunol 147: 4019

    PubMed  Google Scholar 

  6. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L (1991) Bispecific monoclonal antibodies to CD and to a tumor associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 48: 227

    PubMed  Google Scholar 

  7. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR (1990) Refocussing the immune system to react with human tumors by targeting human lymphocytes with bispecific antibodies. Dev Biol Stand 71: 33

    PubMed  Google Scholar 

  8. Garrido MA, Perez P, Titus JA, Valdayo MJ, Winkler DF, Barbieri SA, Wunderlich JR, Segal DM (1990) Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol 144: 2891

    PubMed  Google Scholar 

  9. Helle M, Boeye L, Groot E de, Vos A de, Aarden L (1991) Sensitive ELISA for I-6; detection of IL-6 in biological fluids, synovial fluids and sera. J Immunol Methods 138: 47

    PubMed  Google Scholar 

  10. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 75: 1438

    Google Scholar 

  11. Kerr L, Huntoon C, Donohue J, Leibson PJ, Bander NH, Ghose T, Luner SJ, Vessella R, McKean DJ (1990) Hetero conjugate antibodydirected killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. J Immunol 144: 4060

    PubMed  Google Scholar 

  12. Lau WBM de van Loon AE, Heije K, Valerio D, Bast EJEG (1989) production of hybrid hybridomas based on HATs-neomycinr double mutants. J Immunol Methods 117: 1

    PubMed  Google Scholar 

  13. Leij L de, Postmus PE, Poppema S, Elema JE, The TH (1986) The use of monoclonal antibodies for the pathological diagnosis of lungcancer. In: Hansen HH (ed) Lung cancer: basic and clinical aspects. Nijhof, The Hague, p 31

    Google Scholar 

  14. Mackay CR, Marston WL, Dudler L, Spertini O, Tedder TF, Hein WR (1992) Tissue specific migration pathways by phenotipically distinct subpopulations of memory T cells. Eur J Immunol 22: 887

    PubMed  Google Scholar 

  15. Makgoba MW, Sanders ME, Shaw S (1989) The CD2-LFA3 and LFA1-ICAM pathways: relevance to T-cell recognition. Immunol Today 10: 417

    PubMed  Google Scholar 

  16. Mezzanzanica D, Canevari S, Colnaghi MI (1991) Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int J Clin Lab Res 21: 159

    PubMed  Google Scholar 

  17. Mezzanzanica D, Garido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR, Segal DM, Wunderlich JR (1991) Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res 51: 57

    Google Scholar 

  18. Milstein C, Cuello AC (1984) Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol Today 5: 299

    Google Scholar 

  19. Nishimura T, Nakamura Y, Tsulamoto H, Takeuchi Y, Tokuda Y, Iwasawa M, Yamamoto T, Masuko T, Hashimoto Y, Habu S (1992) Humanc-erbB-2 proto-ongogene product as a target for bispecificantibody directed adoptive tumor immunotherapy. Int J Cancer 50: 800

    PubMed  Google Scholar 

  20. Nitta T, Sato K, Okumura K, Ishii S (1990) Induction of cytotoxicity in human T cells coated with anti-glioma X anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 72: 476

    PubMed  Google Scholar 

  21. Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368

    PubMed  Google Scholar 

  22. Perez P, Titus JA, Lotze MT, Cuttitta F, Longo DL, Groves ES, Rabin H, Durda PJ, Segal DM (1986) Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 137: 2069

    PubMed  Google Scholar 

  23. Rivoltini L, Cattoretti G, Arienti F, Mastroianni A, Melani C, Colombo MP, Parmiani G (1991) The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less differentiated phenotype. Int J Cancer 47: 746

    PubMed  Google Scholar 

  24. Roosnek EE, Lier RA van, Aarden LA (1987) Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation. Eur J Immunol 17: 1507

    PubMed  Google Scholar 

  25. Rosenberg SA, Lotze MT, Muul LM (1987) A progess reprot on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and IL-2 or high dose IL-2 alone. N Engl J Med 316: 889

    Google Scholar 

  26. Rosenberg SA, Schwarz SL, Spiess PJ (1988) Combination immunotherapy for cancer: synergistic anti tumour interactions of interleukin-2, alfa interferon and tumour infiltrating lymphocytes. J Natl Cancer Inst 80: 139

    Google Scholar 

  27. Ségal DM, Qian JH, Andrew SM, Titus JA, Mezzanzanica D, Garrido MA, Wunderlich JR (1991) Cytokine release by peripheral blood lymphocytes targeted with bispecific antibodies, and its role in blocking tumor growth. Ann NY Acad Sci 636: 228

    Google Scholar 

  28. Shaw S, Luce GEG, Quinones R, Gress RE, Springer TA, Sanders ME (1986) Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature 323: 262

    PubMed  Google Scholar 

  29. Shimizu Y, Newman W, Tanaka Y, Shaw S (1992) Lymphocyte interactions with endothelial cells. Immunol Today 13: 106

    PubMed  Google Scholar 

  30. Spits H, Schoten W, Keizer H, Seventer G van, Rijn M van de, Terhorst D, Vries JE de (1986) Alloantigen recognition is preceded by non specific adhesion of cytotoxic T cells and target cells. Science 232: 403

    PubMed  Google Scholar 

  31. Spronk PE, Borg EJ ter, Limburg PC, Kallenberg CGM (1992) Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity. Clin Exp Immunol 90: 106

    PubMed  Google Scholar 

  32. Spurr NK, Durbin H, Sheer D, Parkar M, Bobrow L, Bodmer WF (1986) Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUA-I. Int J Cancer 38: 631

    PubMed  Google Scholar 

  33. Stearz UD, Bevan MJ (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 83: 1453

    PubMed  Google Scholar 

  34. Stearz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 31: 628

    Google Scholar 

  35. Stötter H, Wiebke EA, Tomita A, Belldegrun A, Topilian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell suseptibility to lysis. J Immunol 142: 1767

    PubMed  Google Scholar 

  36. Tax WJM, Reekers HW, Reekers PPM, Capel PJA, Koene RH (1983) Polymorphism in mitogenic effect of IgG monoclonal antibodies against T3 antigen on human T-cell. Nature 304: 445

    PubMed  Google Scholar 

  37. Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S (1990) Expression of intercellular adhesion molecule-I (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 46: 1001

    PubMed  Google Scholar 

  38. Tomkinson BE, Brown MC, IP SH, Carabis S, Sullivan JL (1989) Soluble CD8 during T cell activation. J Immunol 142: 2230

    PubMed  Google Scholar 

  39. Wauwe JP van, Mey JR de, Goosens JG (1980) OKT3: a monoclonal anti-human T-lymphocyte antibody with potent mitogenic properties. J Immunol 124: 2708

    PubMed  Google Scholar 

  40. Weiner GJ, Hillstrom JR (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147: 4035

    PubMed  Google Scholar 

  41. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldhan RK (1987) Constant infusion interleukin 2 in adoptive immunotherapy of advanced cancer. N Engl J Med 3: 898

    Google Scholar 

  42. Woo DV, Li D, Steplewski Z (1989) Selective chromosomal damage and cytotoxicity of 125-I-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res 49: 2952

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology, University Hospital Groningen, Oosterisingel 59, 9713, Groningen, The Netherlands

    B. J. Kroesen, A. ter Haar, H. Spakman, P. C. Limburg, T. H. The & L. de Leij

  2. Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands

    P. Willemse, D. Th. Sleijfer, E. G. E. de Vries & N. H. Mulder

  3. Department of Lung Diseases, University Hospital Groningen, Groningen, The Netherlands

    H. H. Berendsen

Authors
  1. B. J. Kroesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. ter Haar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Spakman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Willemse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Th. Sleijfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. G. E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. H. Berendsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. C. Limburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T. H. The
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L. de Leij
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kroesen, B.J., ter Haar, A., Spakman, H. et al. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 37, 400–407 (1993). https://doi.org/10.1007/BF01526797

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01526797

Key words

Search

Navigation